PTK2B and urinary bladder carcinoma: Our results provide the first evidence of increased levels of nuclear Pyk2 in bladder cancer cells thereby suggesting the novel hypothesis that in bladder cancer cells IGF-I-activated Pyk2 may act not only in the cytoplasm but also translocate into the nucleus, where it might work as a transcription factor.